Page last updated: 2024-08-24

irinotecan and Hodgkin Disease

irinotecan has been researched along with Hodgkin Disease in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's1 (25.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benoit, LT; Cochran, JH; Emmerton, KK; Lau, UY; Senter, PD; Stevens, NS; Zaval, M1
Fujimoto, K; Kaneki, T; Koizumi, T; Kubo, K; Urushihata, K; Yamaguchi, S1
Ariyoshi, Y; Furue, H; Kimura, I; Masaoka, T; Ogawa, M; Oguro, M; Ohno, R; Saito, H; Sakai, Y; Yoshida, Y1
Eckhardt, SG1

Trials

1 trial(s) available for irinotecan and Hodgkin Disease

ArticleYear
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Irinotecan; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma

1994

Other Studies

3 other study(ies) available for irinotecan and Hodgkin Disease

ArticleYear
Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins.
    Molecular pharmaceutics, 2018, 09-04, Volume: 15, Issue:9

    Topics: Animals; Antibodies; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Hodgkin Disease; Humans; Hydrogen-Ion Concentration; Irinotecan; Lactones; Mice; Mice, SCID; Pharmacokinetics

2018
Successful salvage therapy of irinotecan for relapsed Hodgkin's lymphoma.
    Internal medicine (Tokyo, Japan), 2002, Volume: 41, Issue:8

    Topics: Adult; Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Hodgkin Disease; Humans; Irinotecan; Male; Radiography; Recurrence; Salvage Therapy; Topoisomerase I Inhibitors

2002
Irinotecan: a review of the initial phase I trials.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:8 Suppl 6

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; France; Hodgkin Disease; Humans; Irinotecan; Japan; Leukemia; Lymphoma, Non-Hodgkin; United States

1998